Halo Biomedical Investment II Limited - Net Worth and Insider Trading

Halo Biomedical Investment II Limited Net Worth

The estimated net worth of Halo Biomedical Investment II Limited is at least $261 Million dollars as of 2024-06-22. Halo Biomedical Investment II Limited is the 2101 Beneficial owner of ImmuneOnco Biopharmaceuticals (Shanghai) Inc and owns about 18,000,000 shares of ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) stock worth over $261 Million. Details can be seen in Halo Biomedical Investment II Limited's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Halo Biomedical Investment II Limited has not made any transactions after 2023-09-05 and currently still holds the listed stock(s).

Transaction Summary of Halo Biomedical Investment II Limited

Halo Biomedical Investment II Limited Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Halo Biomedical Investment II Limited owns 1 companies in total, including ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) .

Click here to see the complete history of Halo Biomedical Investment II Limited’s form 4 insider trades.

Insider Ownership Summary of Halo Biomedical Investment II Limited

Ticker	Comapny	Transaction Date	Type of Owner
HKSE:01541	ImmuneOnco Biopharmaceuticals (Shanghai) Inc	2023-09-05	2101 Beneficial owner

Halo Biomedical Investment II Limited Latest Holdings Summary

Halo Biomedical Investment II Limited currently owns a total of 1 stock. Halo Biomedical Investment II Limited owns 18,000,000 shares of ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) as of September 5, 2023, with a value of $261 Million.

Latest Holdings of Halo Biomedical Investment II Limited

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
HKSE:01541	ImmuneOnco Biopharmaceuticals (Shanghai) Inc	2023-09-05	18,000,000	14.48	260,640,000

Holding Weightings of Halo Biomedical Investment II Limited

Halo Biomedical Investment II Limited Form 4 Trading Tracker

According to the SEC Form 4 filings, Halo Biomedical Investment II Limited has made a total of 1 transactions in ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) over the past 5 years, including 0 buys and 0 sells. The most-recent trade in ImmuneOnco Biopharmaceuticals (Shanghai) Inc is the sale of 18,000,000 shares on September 5, 2023, which brought Halo Biomedical Investment II Limited around $0.

Insider Trading History of Halo Biomedical Investment II Limited

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Halo Biomedical Investment II Limited Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Halo Biomedical Investment II Limited Ownership Network

Ownership Network List of Halo Biomedical Investment II Limited

No Data

Ownership Network Relation of Halo Biomedical Investment II Limited

Halo Biomedical Investment II Limited Owned Company Details

What does ImmuneOnco Biopharmaceuticals (Shanghai) Inc do?

Who are the key executives at ImmuneOnco Biopharmaceuticals (Shanghai) Inc?

Halo Biomedical Investment II Limited is the 2101 Beneficial owner of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Other key executives at ImmuneOnco Biopharmaceuticals (Shanghai) Inc include Ho Yao , CHENG YIQUAN , and 2102 Investment manager LAV Asset Management (Hong Kong) Limited .

ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) Insider Trades Summary

Over the past 18 months, Halo Biomedical Investment II Limited made no insider transaction in ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541). Other recent insider transactions involving ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) include a net sale of 0 shares made by LAV Asset Management (Hong Kong) Limited , a net sale of 0 shares made by LAV ImmOn Hong Kong Limited , and a net sale of 0 shares made by LAV Biosciences Fund V, L.P. .

In summary, during the past 3 months, insiders sold 0 shares of ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541)'s detailed insider trading history can be found in Insider Trading Tracker table.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Insider Transactions

No Available Data

Halo Biomedical Investment II Limited Mailing Address

Above is the net worth, insider trading, and ownership report for Halo Biomedical Investment II Limited. Currently GuruFocus does not have mailing address information for Halo Biomedical Investment II Limited.

Discussions on Halo Biomedical Investment II Limited

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.